Back to News & Events

New York State Innovation Summit

NYSTAR and FuzeHub invite you to the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. This multi-day event for NYS organizations that want to showcase and discover new and emerging technologies that support innovation and drive business growth. Whether you’re a startup, an economic developer, or an established manufacturer, the NYS Innovation Summit is for you.

The 2021 New York State Innovation Summit will showcase companies and researchers at the forefront of emerging technologies and new advancements in production capabilities. This event celebrates New York State leadership in technology-led economic growth with experts in biotechnology, new materials, energy innovation, and artificial intelligence that will explore current technology convergence opportunities, ways to accelerate commercialization, and issues of manufacturing sustainability.

This year’s Innovation Summit includes the New York State Commercialization Competition and speakers from top companies such as Cree, Plug Power, Velan Studios and Verizon 5G Labs.

For more information, or to register, visit nysinnovationsummit.com.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4906
                    [post_author] => 4
                    [post_date] => 2025-07-17 10:27:09
                    [post_date_gmt] => 2025-07-17 14:27:09
                    [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2667 [post_author] => 3 [post_date] => 2017-04-20 18:25:21 [post_date_gmt] => 2017-04-20 18:25:21 [post_content] => The Center for Biotechnology's Clint Rubin and Diane Fabel recently co-authored a STAT article on the NIH-REACH proof-of-concept program. In 2015, The Center for Biotechnology received one of three national NIH-REACH designations, through which the Long Island Bioscience Hub was established. The article, co-authored by all of the REACH center directors, discusses the importance of REACH-type programs and the impact REACH has been able have in a relatively short amount of time. In just over two years, the three REACH institutions have evaluated over 400 promising product development projects, funding more than 60 experimental treatments and tests that target a wide range of health issues. Read the full text here: https://www.statnews.com/2017/04/17/nih-reach-biomedicine-treatments/ [post_title] => NIH-REACH: Lowering the Barriers that Slow Translation Research [post_excerpt] => Recent STAT article on the NIH-REACH proof-of-concept program authored by CFB's Clinton Rubin and Diane Fabel. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nih-reach-lowering-the-barriers-that-slow-translation-research [to_ping] => [pinged] => [post_modified] => 2017-05-05 19:57:47 [post_modified_gmt] => 2017-05-05 19:57:47 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2667 [menu_order] => 150 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3942 [post_author] => 4 [post_date] => 2022-10-24 15:40:45 [post_date_gmt] => 2022-10-24 15:40:45 [post_content] =>

The Long Island Network for Clinical and Translational Science (LINCATS) is awarding pilot funding of up to $25K per investigator with projects of novel approaches to translational science. This is open to faculty and postdoctoral fellows from the LINCATS network. Up to 8 awards will be granted per year – 4 of which will be provided to principal investigators from collaborating institutions, and 4 for SBU investigators.

Eligibility: All postdoctoral fellows and faculty affiliated with the LINCATS network (Brookhaven National Laboratory, Cold Spring Harbor, Northport VA Medical Center, Stony Brook University and all Stony Brook Medicine-affiliated healthcare locations) are eligible to apply. We will prioritize early career, under-represented groups, women, health disparities-focused clinical and translational science, and collaborative projects across institutions. Preference will be given to non-funded and new lines of research for the applying investigator.

Awardees will also benefit from research support from our Research Concierge, providing aid in:

Regulatory submission through approval
Data Capture and OnCore subject tracking
Pilot Tracking, to ensure the project meets specified milestones, including timely reporting
Resource Access to all LINCATS services
Monitoring and projecting study budgets

Learn more and click here to apply: https://www.stonybrookmedicine.edu/LINCATS/LINCATSPilots

[post_title] => Pilot Awards for Translational Science: LINCATS [post_excerpt] => The Long Island Network for Clinical and Translational Science (LINCATS) is awarding pilot funding of up to $25K per investigator with projects of novel approaches to translational science. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pilot-awards-for-translational-science-lincats [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:41:18 [post_modified_gmt] => 2023-07-10 16:41:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3942 [menu_order] => 16 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3652 [post_author] => 3 [post_date] => 2021-02-03 16:41:22 [post_date_gmt] => 2021-02-03 16:41:22 [post_content] =>

BARDA is interested in learning more about the current landscape and technologies and companies in the needle-less delivery space. The delivery platforms should be compatible with biologic payloads (e. g. vaccines, monoclonal antibodies) that utilize the following alternative routes of administration:
- Oral
- Buccal/Sublingual
- Inhalation (e. g. aerosolization)
Other platforms

Technologies NOT of interest:
- Needle-based (e.g. auto injectors)
- Microneedle systems (e. g. patches)
- Implant-based

Particular interest in plug-and-play platforms that have potential to easily allow for the use of a wide variety of vaccines or therapeutics with the platform.

If you are interested in sharing information, please contact Phuong Nguyen at phuong.t.nguyen@stonybrook.edu

[post_title] => BARDA RFI: Needle-less Delivery [post_excerpt] => BARDA is interested in learning more about the current landscape and technologies and companies in the needle-less delivery space. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-rfi-needle-less-delivery [to_ping] => [pinged] => [post_modified] => 2024-12-03 15:01:25 [post_modified_gmt] => 2024-12-03 20:01:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3652 [menu_order] => 54 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4906 [post_author] => 4 [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 [post_content] =>

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 282 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology

More Information

NIH-REACH: Lowering the Barriers that Slow Translation Research

More Information

Pilot Awards for Translational Science: LINCATS

More Information

BARDA RFI: Needle-less Delivery

More Information